var title_f4_46_4832="Bilateral cryptorchidism2";
var content_f4_46_4832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral undescended testicles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4832=[""].join("\n");
var outline_f4_46_4832=null;
var title_f4_46_4833="Acipimox: International drug information";
var content_f4_46_4833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acipimox: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nedios (NL);",
"     </li>",
"     <li>",
"      Olbemox (DE);",
"     </li>",
"     <li>",
"      Olbetam (AT, BE, BR, CH, CZ, DK, FI, GB, HU, IE, IT, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy for the treatment of type IIa, IIb, and IV lipid disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 500-750 mg/day in divided doses with meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 250 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10488 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4833=[""].join("\n");
var outline_f4_46_4833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323562\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977592\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977595\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977588\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821207\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977594\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_46_4834="Colonoscopy PI";
var content_f4_46_4834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Colonoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a colonoscopy, you lie on your side and the doctor or nurse puts a thin tube with a camera into your anus (from behind). Then the doctor or nurse advances the tube into the rectum and colon. The camera sends video pictures from inside your colon to a television screen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4834=[""].join("\n");
var outline_f4_46_4834=null;
var title_f4_46_4835="Malignant gastric ulcer Endosc";
var content_f4_46_4835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant and benign gastric ulcer: Endoscopic appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy showing the differences between the endoscopic appearance of malignant and benign gastric ulcers.",
"    <br/>",
"    (A) Retroflexed views were required on endoscopy to detect this malignant gastric ulcer of the cardia. Note the absence of folds radiating to the base and the exophytic appearance. Biopsies confirmed the presence of adenocarcinoma.",
"    <br/>",
"    (B) Benign gastric ulcer in the prepyloric region. The ulcer is well-circumscribed with folds radiating to the ulcer base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4835=[""].join("\n");
var outline_f4_46_4835=null;
var title_f4_46_4836="Gatifloxacin: Drug information";
var content_f4_46_4836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gatifloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/31/44531?source=see_link\">",
"    see \"Gatifloxacin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/19/35123?source=see_link\">",
"    see \"Gatifloxacin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zymaxid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zymar&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bacterial conjunctivitis:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Zymar&trade;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Days 1 and 2: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Days 3-7: Instill 1 drop into affected eye(s) 4 times/day while awake",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Zymaxid&trade;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Day 1: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Days 2-7: Instill 1 drop into affected eye(s) 2-4 times/day while awake",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/19/35123?source=see_link\">",
"      see \"Gatifloxacin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bacterial conjunctivitis: Children &ge;1 year: Ophthalmic: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zymaxid&trade;: 0.5% (2.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14182372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zymar&trade;: 0.3% (1 mL, 2.5 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10437904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye, fingers, or other surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of bacterial conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctival irritation, discharge, dry eye, edema, irritation, keratitis, lacrimation increased, pain, papillary conjunctivitis, visual acuity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, blepharitis (allergic), chemosis, conjunctival cyst, conjunctival hemorrhage, corneal deposits, corneal disorder, corneal ulcer, dermatitis, dizziness, endophthalmitis, eye redness, iritis, keratoconjunctivitis, macular edema, nausea, paresthesia (oral), photophobia, pruritus, subepithelial opacities, tinnitus, tremor, urticaria, uveitis, vision blurred, throat sore",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zymaxid&trade;: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zymar&trade;: Hypersensitivity to gatifloxacin, other quinolones, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Contact lenses should not be worn during treatment of ophthalmic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic solution: For topical ophthalmic use only. Do not inject ophthalmic solution subconjunctivally or introduce directly into the anterior chamber of the eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gatifloxacin has been shown to be fetotoxic in animal studies. Quinolone exposure during human pregnancy has been reported with other agents (refer to Ciprofloxacin (Systemic), Ofloxacin (Systemic), and Norfloxacin monographs). Following ophthalmic administration, serum concentrations of gatifloxacin are below the limits of quantification (&lt;5 ng/mL). Systemic absorption would be required in order for gatifloxacin to cross the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F177109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other quinolones are known to be excreted in breast milk. The manufacturer recommends using caution if gatifloxacin is administered while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zymaxid Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (2.5 mL): $123.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F177098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bonoq (DE);",
"     </li>",
"     <li>",
"      Bonoq-Uro (DE);",
"     </li>",
"     <li>",
"      Fudixing (CL);",
"     </li>",
"     <li>",
"      Gaticin (ID);",
"     </li>",
"     <li>",
"      Gatif (AR, CN);",
"     </li>",
"     <li>",
"      Gatiflo (JP, KP);",
"     </li>",
"     <li>",
"      Gatilox (PY);",
"     </li>",
"     <li>",
"      Gatimax (ID);",
"     </li>",
"     <li>",
"      Itiflox (PH);",
"     </li>",
"     <li>",
"      Poengatif (PE, UY);",
"     </li>",
"     <li>",
"      Starox (CN);",
"     </li>",
"     <li>",
"      Tequin (AU, BR, MX, MY, SG, ZA);",
"     </li>",
"     <li>",
"      Zequin (PK);",
"     </li>",
"     <li>",
"      Zhu Ning (CL);",
"     </li>",
"     <li>",
"      Zymar (BR, CN, IL, MY, PH, SG, TH, ZA);",
"     </li>",
"     <li>",
"      Zymaran (AR, CO, EC, PE);",
"     </li>",
"     <li>",
"      Zyquin (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gatifloxacin is a DNA gyrase inhibitor, and also inhibits topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption: Ophthalmic: Not measurable (&lt;5 ng/mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Straley CM, Cecil EJ, and Herriman MP, &ldquo;Gatifloxacin Interference With Opiate Urine Drug Screen,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(3):435-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/46/4836/abstract-text/16503726/pubmed\" id=\"16503726\" target=\"_blank\">",
"        16503726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8928 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4836=[""].join("\n");
var outline_f4_46_4836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177127\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177128\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177153\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177131\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177146\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177132\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896355\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896356\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182372\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177085\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10437904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177101\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177151\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177105\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177089\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299391\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220595\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177096\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177108\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177139\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177109\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177107\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177098\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177111\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177088\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177104\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/31/44531?source=related_link\">",
"      Gatifloxacin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/19/35123?source=related_link\">",
"      Gatifloxacin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_46_4837="Paregoric: Patient drug information";
var content_f4_46_4837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paregoric: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/32/20997?source=see_link\">",
"     see \"Paregoric: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/61/43988?source=see_link\">",
"     see \"Paregoric: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paregoric or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10949 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4837=[""].join("\n");
var outline_f4_46_4837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012888\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012887\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012892\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012893\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012895\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012890\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012891\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012896\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012897\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/32/20997?source=related_link\">",
"      Paregoric: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/61/43988?source=related_link\">",
"      Paregoric: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_46_4838="Wrist hand bones";
var content_f4_46_4838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Bones of the hand and wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palmar view of the wrist and hand bones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4838=[""].join("\n");
var outline_f4_46_4838=null;
var title_f4_46_4839="Neonatal chlamydia conjunctivitis";
var content_f4_46_4839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Neonatal chlamydia conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Twelve-day-old with five-day history of progressive lid swelling and discharge typical of chlamydial conjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd Edition. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4839=[""].join("\n");
var outline_f4_46_4839=null;
var title_f4_46_4840="Fusion beats tutorial";
var content_f4_46_4840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1085px;\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Fusion beats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 124px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rhythm strip in a patient with sustained ventricular tachycardia shows a fusion beat and a capture beat. The fusion beat occurs when a supraventricular impulse (following the first P wave) causes ventricular activation which fuses with the complex originating in the ventricle, producing a hybrid complex. The complex following the second P wave has the appearance of a normal QRS complex and is known as a capture beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4840=[""].join("\n");
var outline_f4_46_4840=null;
var title_f4_46_4841="Genetics and pathogenesis of methemoglobinemia";
var content_f4_46_4841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics and pathogenesis of methemoglobinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Josef T Prchal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4841/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/46/4841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobinemia occurs when an imbalance due to either increased methemoglobin production or decreased methemoglobin reduction is present. Inherited and acquired processes by which methemoglobin is produced and reduced will be described here. The diagnosis and treatment of methemoglobinemia is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHEMOGLOBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobin is an altered state of hemoglobin in which the ferrous (Fe2+) irons of heme are oxidized to the ferric (Fe3+) state. The ferric hemes of methemoglobin are",
"    <strong>",
"     unable",
"    </strong>",
"    to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/1\">",
"     1",
"    </a>",
"    ]; as a result, the oxygen dissociation curve is \"left-shifted\" and oxygen delivery to the tissues is impaired (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the patient with increased concentrations of methemoglobin has a functional anemia, to the extent that the circulating methemoglobin-containing molecules are unable to carry oxygen, and the remaining hemoglobin, because of its increased oxygen affinity, has a decreased ability to deliver oxygen to the tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the formation of oxyhemoglobin from deoxyhemoglobin and molecular oxygen, one electron is partially transferred from heme iron to the bound oxygen, forming a ferric-superoxide anion complex (Fe3+&mdash;O2-) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/2\">",
"     2",
"    </a>",
"    ]. During deoxygenation, most of the oxygen leaves the molecule as molecular oxygen, but a small amount leaves as a superoxide (O2-) radical. Under the latter circumstance, the partially transferred electron is not returned to the iron moiety, leaving the heme iron in the ferric state (ie, methemoglobin). This autooxidation of hemoglobin occurs spontaneously at a slow rate in normal individuals, converting 0.5 to 3 percent of the available hemoglobin to methemoglobin per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methemoglobin is also formed from the oxidation of hemoglobin heme iron via reactions with free radicals and endogenous compounds, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    (H2O2), nitric oxide (NO), O2-, and hydroxyl radical (OH&bull;) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Exogenous compounds may oxidize hemoglobin to methemoglobin directly, by means of a metabolic derivative or by generating O2- and H2O2 during their metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once formed, methemoglobin can be reduced back to hemoglobin either enzymatically or nonenzymatically via a number of pathways, only one of which is physiologically important (",
"    <a class=\"graphic graphic_figure graphicRef53599 \" href=\"UTD.htm?24/8/24718\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cytochrome b5 reductase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only physiologically important pathway for reducing methemoglobin back to hemoglobin is the NADH-dependent reaction catalyzed by cytochrome b5 reductase (b5R). Cytochrome b5R, previously known as diaphorase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/7\">",
"     7",
"    </a>",
"    ] and also as methemoglobin reductase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/8\">",
"     8",
"    </a>",
"    ], contains a noncovalently bound prosthetic FAD group that acts as an electron acceptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. NADH generated from glycolysis reduces FAD to FADH2 which then reduces the heme protein cytochrome b5. Electrons from the reduced cytochrome b5 are in turn transferred to methemoglobin, reducing iron back to the ferrous state (",
"    <a class=\"graphic graphic_figure graphicRef53599 \" href=\"UTD.htm?24/8/24718\">",
"     figure 2",
"    </a>",
"    ). The genetics, function, and deficiency of this protein are described in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     NADPH-methemoglobin reductase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative, pathway for reduction of methemoglobin is mediated by NADPH-(flavin) methemoglobin reductase. This pathway uses NADPH generated by glucose-6-phosphate dehydrogenase (G6PD) in the hexose monophosphate (pentose phosphate) shunt as a source of electrons. However, there is normally no electron carrier present in red blood cells to interact with NADPH. As a result, electron acceptors or redox dyes, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , and riboflavin&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef53599 \" href=\"UTD.htm?24/8/24718\">",
"     figure 2",
"    </a>",
"    ) can activate this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Since these electron acceptors are not physiologic, this electron transfer is not significant under normal conditions and NADPH methemoglobin reductase deficiency does not cause methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    administered in the treatment of methemoglobinemia serves as an exogenous electron acceptor, bypassing congenital blocks in the cytochrome b5 reductase pathway, or correcting an acute toxic methemoglobinemia that overwhelms the reducing power of cytochrome b5 reductase. However, in individuals with G6PD deficiency, the use of methylene blue is potentially dangerous since it is a compound with oxidant potential and may produce hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antioxidant protein 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A balance to methemoglobin formation is antioxidant protein 2 (AOP2), which is present in high concentrations in human and mouse red cells. This member of the peroxiredoxin protein family binds to hemoglobin and prevents spontaneous, as well as oxidant-induced, methemoglobin formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobin can be reduced directly by ascorbic acid, reduced glutathione, riboflavin, tetrahydropterin, cysteine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/20/37184?source=see_link\">",
"     cysteamine",
"    </a>",
"    , 3-hydroxyanthranilic acid, and 3-hydroxykynurenine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/5\">",
"     5",
"    </a>",
"    ]. These reactions occur slowly and play a minor role in methemoglobin reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, the formation and reduction of methemoglobin by the mechanisms described above act to maintain a steady-state level of methemoglobin of about 1 percent of total hemoglobin. Methemoglobinemia occurs when there is an imbalance between these two processes; causes are either acquired or congenital, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CYTOCHROME B5 REDUCTASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytochrome b5 reductase is a housekeeping enzyme and a member of the flavoenzyme family of dehydrogenases-electron transferases. It is involved in the transfer of electrons from NADH generated by glyceraldehyde 3-phosphate reduction in the glycolytic pathway to cytochrome b5 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. An understanding of the genetics and biochemistry of cytochrome b5 reductase is important for appreciating the manifestations of the syndromes associated with cytochrome b5 reductase deficiency described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytochrome b5 reductase gene locus (DIA1) has been mapped to chromosome 22 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/21\">",
"     21",
"    </a>",
"    ]. The cytochrome b5R3 gene is approximately 31 kilobases long [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/22\">",
"     22",
"    </a>",
"    ] and has several potential transcripts generating multiple isoforms. Differences at the 5' end of rat liver and reticulocyte cDNAs suggest the use of alternative promoters for the production of all forms of cytochrome b5 reductase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two putative promoters with different characteristics have been well described. A constitutive promoter region has similarities with housekeeping genes as it does not contain a TATA box or CAAT box but instead contains five GC box sequences (GGGCGG and CCGCCC), representing potential binding sites for the transcription factor Sp1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/22\">",
"     22",
"    </a>",
"    ]. The erythroid-specific promoter region contains several possible regulatory elements found in erythroid promoter regions, including a TATA box, CAAT-like sequences, two binding sites for the erythroid-specific transcription factor GATA-1, and a GT box [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/24\">",
"     24",
"    </a>",
"    ]. Two additional promoter regions have been identified but not yet fully characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Isoforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple isoforms of cytochrome b5 reductase are generated from a single gene by a combination of alternative promoters and alternative initiation of translation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. One isoform, found in nonerythroid cells and reticulocytes but not in mature erythrocytes, is a membrane-associated isoform located on the endoplasmic reticulum membrane and the outer mitochondrial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This membrane-bound enzyme is an amphophilic protein consisting of a 275 amino acid hydrophilic moiety that contains the active site and a hydrophobic domain at the NH2-terminal end that anchors the protein to the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other isoforms are found solely in erythroid cells. The isoform involved in methemoglobin reduction is soluble and consists of the same 275 hydrophilic amino acids found in the ubiquitously expressed membrane-associated isoform [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The other erythroid-specific isoform is membrane-associated with an N-terminal hydrophobic sequence that differs from the sequence found in the soluble isoform [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/24\">",
"     24",
"    </a>",
"    ]. Although it contributes only 20 to 25 percent of erythrocyte cytochrome b5 reductase activity in adult humans, it represents a greater proportion in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/34\">",
"     34",
"    </a>",
"    ]. The function of this isoform is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THE HEREDITARY METHEMOGLOBINEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first case of congenital methemoglobinemia was probably reported by Francois in 1845 when he described one of his patients with chronic congenital cyanosis without obvious cardiac or pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/35\">",
"     35",
"    </a>",
"    ]. A familial incidence of \"autotoxic cyanosis\" and methemoglobinemia was later described by Hitzenberger in 1932 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/36\">",
"     36",
"    </a>",
"    ]. Historic accounts of early work on this disorder are available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three types of hereditary methemoglobinemia. Two are inherited as autosomal recessive traits: cytochrome b5 reductase deficiency and cytochrome b5 deficiency. The third type is an autosomal dominant disorder, hemoglobin M (Hb M) disease in which there is a mutation in the globin molecule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"     \"Unstable hemoglobin variants\"",
"    </a>",
"    .) Most cases of hereditary methemoglobinemia are due to a deficiency of cytochrome b5 reductase, while only a single case of cytochrome b5 deficiency has been reported. Each of these is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cytochrome b5 reductase 3 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type I cytochrome b5 reductase 3 (cyb5R3) deficiency only erythrocytes have decreased enzyme activity. This enzyme is heat-labile and presumably is unstable and easily degraded. Thus, although cytochrome b5R is abnormal in all cells in type I deficiency, only mature red cells, which cannot synthesize proteins and replace the enzyme, are significantly affected. Since cytochrome b5R is coded by a single gene, it is hypothesized that type I cytochrome b5R deficiency results from mutations producing an unstable enzyme, while mutations in type II deficiency either affect the catalytic function or cause underproduction of the enzyme, resulting in a generalized decrease in functional cytochrome b5R activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of enzymopenic congenital methemoglobinemia are type I, in which the functional deficiency of cytochrome b5 reductase is limited to erythrocytes. Homozygotes or compound heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] have methemoglobin concentrations of 10 to 35 percent and appear cyanotic but are usually asymptomatic even with levels up to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/43\">",
"     43",
"    </a>",
"    ]. Some patients have reported nonspecific symptoms of headache and easy fatigability. Life expectancy is not shortened and pregnancies occur normally. Significant compensatory polycythemia (erythrocytosis) is only rarely observed. The cyanosis is of cosmetic significance only, but can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    or ascorbic acid, both of which facilitate the reduction of methemoglobin through alternate pathways (see",
"    <a class=\"local\" href=\"#H6\">",
"     'NADPH-methemoglobin reductase pathway'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the asymptomatic, chronically methemoglobinemic homozygotes (or compound heterozygotes), heterozygous individuals are at risk for developing acute, symptomatic methemoglobinemia after exposure to exogenous methemoglobin-inducing agents. The classic description of acute toxic methemoglobinemia in United States military personnel receiving malarial prophylaxis in Vietnam demonstrated for the first time that heterozygotes for an autosomal recessive disease can, under certain conditions, develop a disease state that is more clinically significant than their asymptomatic homozygous peers. In contrast, homozygotes for enzyme deficiency, because of the chronicity of their methemoglobinemia, are fully accommodated to their disease state, in part by an increase of their erythrocyte mass [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type I cytochrome b5 reductase 3 deficiency is distributed worldwide but is endemic in the Athabascan Alaskans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], Navajo Indians [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/48\">",
"     48",
"    </a>",
"    ], and Yakutsk natives of Siberia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The Navajo Indians and the Athabascan Indians of Alaska are known to share a common ancestor; thus, the high frequency of cytochrome b5R deficiency suggests a common origin for all three of these populations. However, it remains to be determined if the molecular defect resulting in cytochrome b5R deficiency is identical in these populations. In other ethnic and racial groups the defect occurs sporadically. Although cyanosis is difficult to detect due to skin pigmentation, type I deficiency has been reported in two unrelated African-American families [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several point mutations in patients with type I cytochrome b5 reductase 3 deficiency have been reported; all are missense mutations, resulting in an amino acid substitution. Three of these mutations are found in the 5' end of the cytochrome b5R gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A fourth mutation, a G to A transition in exon 8 (E212K) in an African-American family, occurs in the 3' end [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional mutation, resulting in the replacement of threonine by serine at codon 116, is found in exon 5 (T116S) in African-Americans with type I cytochrome b5 reductase 3 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/55\">",
"     55",
"    </a>",
"    ]. However, this mutation is not responsible for the enzyme deficiency, since this amino acid substitution causes no readily appreciable disruption of the b5R secondary structure. This missense mutation has been shown to be a high frequency polymorphism of cytochrome b5R specific for African-Americans. It is one of the commonest, African-specific polymorphisms known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type II cytochrome b5 reductase 3 deficiency, which represents 10 to 15 percent of cases of enzymopenic congenital methemoglobinemia, cytochrome b5R is deficient in all cells. Type II cytochrome b5R deficiency has a sporadic distribution. In addition to methemoglobinemia and cyanosis, patients exhibit mental retardation and developmental delay with failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/56\">",
"     56",
"    </a>",
"    ]. Other neurologic symptoms are often present, including microcephaly, opisthotonus, athetoid movements, strabismus, seizures, and spastic quadriparesis. Life expectancy is significantly shortened; most individuals die in infancy. The mechanism resulting in the neurologic problems is currently unknown but may be due to abnormal lipid elongation and desaturation in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/57\">",
"     57",
"    </a>",
"    ], or perhaps due to impairment of ferri-iron reduction of other cellular globins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type II mutations have been reported in both the 5' and 3' ends of the cytochrome b5R gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/59-65\">",
"     59-65",
"    </a>",
"    ]. Type II mutations are heterogeneous, including deletions, point mutations, splicing site mutations, and premature stop codons, whereas all the mutations found in the type I individuals have been missense mutations. Unlike type I mutations that are red cell confined, type II mutations are associated with b5R deficiency of all cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemoglobin M disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another cause of congenital cyanosis is hemoglobin M disease. Hemoglobin M is due to mutations in either the alpha, beta, or gamma globin molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. In most of the mutations, tyrosine has been substituted for either the proximal or distal histidine in the heme pocket, and forms an iron-phenolate complex that resists reduction to the divalent state. Hb M differs in a number of ways from other hemoglobins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has an abnormal pattern of spectrophotometric absorbance",
"     </li>",
"     <li>",
"      It may migrate abnormally on hemoglobin electrophoresis, especially if this is performed at pH 7.1, a pH at which the imidazole groups of histidine have a net positive charge. However, a normal hemoglobin electrophoresis does not rule out the presence of Hb M.",
"     </li>",
"     <li>",
"      It differs in its reactivity to cyanide and azide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive diagnosis of Hb M disease can be made via peptide or DNA analysis. At least seven different mutations leading to the clinical phenotype of Hb M disease have been described to date, and a library of mutations is available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/67\">",
"     67",
"    </a>",
"    ]. There is no effective treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"     \"Unstable hemoglobin variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cytochrome b5 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytochrome b5 serves as an electron donor in a variety of reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In RBCs, it transfers electrons to methemoglobin to reduce it to hemoglobin.",
"     </li>",
"     <li>",
"      In cells with mitochondria, a reaction catalyzed by stearyl-CoA desaturase transfers electrons from cytochrome b5 to stearyl-CoA in the outer mitochondrial membrane and endoplasmic reticulum [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/69\">",
"       69",
"      </a>",
"      ]. These reactions play an important role in fatty acid desaturation and drug metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deficiency of cytochrome b5 is an extremely rare disorder that causes congenital methemoglobinemia. Only one well documented case of cytochrome b5 deficiency has been described, compared with over 500 reported cases of cytochrome b5 reductase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/70\">",
"     70",
"    </a>",
"    ]. This patient, a product of an Israeli consanguineous marriage, was also a male pseudohermaphrodite. Further analysis revealed that he was homozygous for a splicing mutation in the cytochrome b5 gene, resulting in a premature stop codon and a truncated protein molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/71\">",
"     71",
"    </a>",
"    ]. Another family with probable cytochrome b5 deficiency was described prior to the recognition of this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the inheritance pattern in this family was autosomal dominant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590826\">",
"    <span class=\"h1\">",
"     ACQUIRED/ACUTE TOXIC METHEMOGLOBINEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590834\">",
"    <span class=\"h2\">",
"     Drugs and exogenous agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of methemoglobinemia are acquired, resulting from increased methemoglobin formation by various exogenous agents (",
"    <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/66,73\">",
"     66,73",
"    </a>",
"    ]. Methemoglobinemia may occur as a result of medication overdoses or poisoning, but may also occur at standard doses, particularly in individuals with partial deficiencies of cytochrome b5R [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/45,74\">",
"     45,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 138 cases of acquired methemoglobinemia, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    accounted for 42 percent of all affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/75\">",
"     75",
"    </a>",
"    ]. Dapsone is apparently also used in some \"street drugs\", and may therefore be a cause for otherwise unexplained acquired methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590841\">",
"    <span class=\"h2\">",
"     Topical anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of acquired methemoglobinemia is the use of topical anesthetic agents, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    , during invasive procedures (eg, bronchoscopy, endoscopy, transesophageal echocardiography (TEE), intubation) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report dealing with results of 28,478 TEE studies, 19 cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    -induced methemoglobinemia were identified, for an incidence of 0.067 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/78\">",
"     78",
"    </a>",
"    ]. The mean methemoglobin level was 32 &plusmn; 15 percent (mean &plusmn; 1 SD). When compared with a random sample of 190 patients undergoing TEE, patients developing methemoglobinemia were significantly more likely to be hospitalized (90 versus 58 percent), anemic (84 versus 45 percent), and have active systemic infection at the time of TEE (68 versus 7 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=see_link&amp;anchor=H3#H3\">",
"     \"Transesophageal echocardiography: Indications, complications, and normal views\", section on 'Safety of TEE examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Methemoglobinemia may be clinically suspected in this setting by the presence of clinical \"cyanosis\" and a normal arterial PO2 (PaO2) as obtained by arterial blood gases,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of \"chocolate brown blood\" in the operative field [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590848\">",
"    <span class=\"h2\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and premature infants are particularly susceptible to the development of methemoglobinemia because their erythrocyte b5R activity is normally 50 to 60 percent of adult activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Although cytochrome b5R levels rise to those of an adult within months of birth, young infants are unusually vulnerable to developing toxic methemoglobinemia following exposure to a number of otherwise relatively harmless medications, local ointments, and dyes used on diapers.",
"   </p>",
"   <p>",
"    Methemoglobinemia has also been associated with diarrheal illnesses in infants without known toxin exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The exact mechanism leading to methemoglobinemia is unknown but may be due to increased endogenous nitrite production, milk intolerance, or unique bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/85\">",
"     85",
"    </a>",
"    ]. An association between methemoglobinemia and weight in the lower percentiles has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3816429\">",
"    <span class=\"h3\">",
"     Contaminated well water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired methemoglobinemia in infants and children can be especially severe upon ingestion of nitrates that may contaminate well water in rural areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/88\">",
"     88",
"    </a>",
"    ]. Nitrates do not oxidize hemoglobin directly; intestinal bacteria convert the nitrates to nitrites, which then oxidize hemoglobin to methemoglobin. In the United States, formula and food prepared from well water contaminated with nitrates poses the greatest risk of developing methemoglobinemia in infants and children (&ldquo;blue baby syndrome&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. The nitrate nitrogen concentration of water should be &lt;10 ppm (&lt;10",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    to avoid methemoglobinemia.",
"   </p>",
"   <p>",
"    For those using private water supplies to prepare formula and food for infants and children, annual or semiannual testing should be performed to assure that nitrate levels are &lt;10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and nitrite levels are &lt;1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4841/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Otherwise, such water should not be employed. Methemoglobinemia does not occur in breastfed infants of mothers who ingest nitrate-contaminated water because nitrates do not concentrate in breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590453\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobin is an altered state of hemoglobin in which the ferrous (Fe2+) irons of heme are oxidized to the ferric (Fe3+) state. The ferric hemes of methemoglobin are unable to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased and oxygen delivery to the tissues is impaired. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Methemoglobin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590554\">",
"    <span class=\"h2\">",
"     Formation of methemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobinemia occurs when either increased methemoglobin production or decreased methemoglobin reduction is present. These causes can be either inherited or acquired.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The autooxidation of hemoglobin to methemoglobin occurs spontaneously at a slow rate in normal individuals, converting 0.5 to 3 percent of the available hemoglobin to methemoglobin per day. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once formed, methemoglobin can be reduced back to hemoglobin via two potential pathways (",
"      <a class=\"graphic graphic_figure graphicRef53599 \" href=\"UTD.htm?24/8/24718\">",
"       figure 2",
"      </a>",
"      ): physiological cytochrome B5 reductase and a pathway that can be activated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      administration (ie, NADPH-methemoglobin reductase). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normally, the formation and reduction of methemoglobin by these mechanisms maintain a steady-state level of methemoglobin of about 1 percent of total hemoglobin. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normal values'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cyanosis from methemoglobinemia is clinically detected at about 8 to 12 percent methemoglobin.",
"     </li>",
"     <li>",
"      Acquired methemoglobinemia is life threatening when methemoglobin levels exceed 30 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590561\">",
"    <span class=\"h2\">",
"     Hereditary methemoglobinemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of hereditary methemoglobinemia. Two are inherited as autosomal recessive traits: cytochrome b5 reductase deficiency and cytochrome b5 deficiency. The third type is an autosomal dominant disorder, hemoglobin M (Hb M) disease in which there is a mutation in the globin molecule. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'The hereditary methemoglobinemias'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11590576\">",
"    <span class=\"h2\">",
"     Acquired methemoglobinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of methemoglobinemia are acquired, resulting from increased methemoglobin formation by various exogenous agents (",
"    <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"     table 1",
"    </a>",
"    ). Methemoglobinemia may also occur as a result of medication given at standard doses, particularly in individuals with partial deficiencies of cytochrome B5 reductase. Commonly implicated agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , topical anesthetics, and nitrates in infants and children. (See",
"    <a class=\"local\" href=\"#H11590826\">",
"     'Acquired/acute toxic methemoglobinemia'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/1\">",
"      Darling R, Roughton F. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942; 137:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/2\">",
"      Misra HP, Fridovich I. The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem 1972; 247:6960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/3\">",
"      EDER HA, FINCH C, McKEE RW. Congenital methemoglobinemia; a clinical and biochemical study of a case. J Clin Invest 1949; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/4\">",
"      JAFFE ER, NEURMANN G. A COMPARISION OF THE EFFECT OF MENADIONE, METHYLENE BLUE AND ASCORBIC ACID ON THE REDUCTION OF METHEMOGLOBIN IN VIVO. Nature 1964; 202:607.",
"     </a>",
"    </li>",
"    <li>",
"     Jaffe E, Hultquist D. Cytochrome b5 reductase deficiency and enzymopenic hereditary methemoglobinemia. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver C, Beaudet A, Sly W, Valle D (Eds), McGraw Hill, New York 1995. Vol 3, p.3399.",
"    </li>",
"    <li>",
"     Feelisch M, Kubitzek D, Werringloer J. The oxyhemoglobin assay. In: Methods in Nitric Oxide Research, Feelisch M, Stamler J (Eds), John Wiley and Sons, New York 1996. p.453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/7\">",
"      SCOTT EM, GRIFFITH IV. The enzymic defect of hereditary methemoglobinemia: diaphorase. Biochim Biophys Acta 1959; 34:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/8\">",
"      GIBSON QH. The reduction of methaemoglobin in red blood cells and studies on the cause of idiopathic methaemoglobinaemia. Biochem J 1948; 42:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/9\">",
"      SCOTT EM, McGRAW JC. Purification and properties of diphosphopyridine nucleotide diaphorase of human erythrocytes. J Biol Chem 1962; 237:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/10\">",
"      Passon PG, Hultquist DE. Soluble cytochrome b 5 reductase from human erythrocytes. Biochim Biophys Acta 1972; 275:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/11\">",
"      Kuma F, Ishizawa S, Hirayama K, Nakajima H. Studies on methemoglobin reductase. I. Comparative studies of diaphorases from normal and methemoglobinemic erythrocytes. J Biol Chem 1972; 247:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/12\">",
"      Kiese M. Die reduktion des hamiglobins. Biochem Z 1944; 316:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/13\">",
"      Warburg O, Kubowitz F, Christian W. Uber die katalytische wirkung von methlenblau in lebenden zellen. Biochem Z 1930; 227:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/14\">",
"      Yubisui T, Takeshita M, Yoneyama Y. Reduction of methemoglobin through flavin at the physiological concentration by NADPH-flavin reductase of human erythrocytes. J Biochem 1980; 87:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/15\">",
"      Sass MD, Caruso CJ, Farhangi M. TPNH-methemoglobin reductase deficiency: a new red-cell enzyme defect. J Lab Clin Med 1967; 70:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/16\">",
"      Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 75:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/17\">",
"      Stuhlmeier KM, Kao JJ, Wallbrandt P, et al. Antioxidant protein 2 prevents methemoglobin formation in erythrocyte hemolysates. Eur J Biochem 2003; 270:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/18\">",
"      Maran J, Guan Y, Ou CN, Prchal JT. Heterogeneity of the molecular biology of methemoglobinemia: a study of eight consecutive patients. Haematologica 2005; 90:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/19\">",
"      Iyanagi T, Watanabe S, Anan KF. One-electron oxidation-reduction properties of hepatic NADH-cytochrome b5 reductase. Biochemistry 1984; 23:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/20\">",
"      Strittmatter P. The reaction sequence in electron transfer in the reduced nicotinamide adenine dinucleotide-cytochrome b5 reductase system. J Biol Chem 1965; 240:4481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/21\">",
"      Bull PC, Shephard EA, Povey S, et al. Cloning and chromosomal mapping of human cytochrome b5 reductase (DIA1). Ann Hum Genet 1988; 52:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/22\">",
"      Tomatsu S, Kobayashi Y, Fukumaki Y, et al. The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. Gene 1989; 80:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/23\">",
"      Pietrini G, Carrera P, Borgese N. Two transcripts encode rat cytochrome b5 reductase. Proc Natl Acad Sci U S A 1988; 85:7246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/24\">",
"      Pietrini G, Aggujaro D, Carrera P, et al. A single mRNA, transcribed from an alternative, erythroid-specific, promoter, codes for two non-myristylated forms of NADH-cytochrome b5 reductase. J Cell Biol 1992; 117:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/25\">",
"      Mota Vieira L, Kaplan JC, Kahn A, Leroux A. Heterogeneity of the rat NADH-cytochrome-b5-reductase transcripts resulting from multiple alternative first exons. Eur J Biochem 1994; 220:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/26\">",
"      Bulbarelli A, Valentini A, DeSilvestris M, et al. An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans. Blood 1998; 92:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/27\">",
"      Tamura M, Yubisui T, Takeshita M, et al. Structural comparison of bovine erythrocyte, brain, and liver NADH-cytochrome b5 reductase by HPLC mapping. J Biochem 1987; 101:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/28\">",
"      Borgese N, Pietrini G. Distribution of the integral membrane protein NADH-cytochrome b5 reductase in rat liver cells, studied with a quantitative radioimmunoblotting assay. Biochem J 1986; 239:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/29\">",
"      Zenno S, Hattori M, Misumi Y, et al. Molecular cloning of a cDNA encoding rat NADH-cytochrome b5 reductase and the corresponding gene. J Biochem 1990; 107:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/30\">",
"      Yubisui T, Naitoh Y, Zenno S, et al. Molecular cloning of cDNAs of human liver and placenta NADH-cytochrome b5 reductase. Proc Natl Acad Sci U S A 1987; 84:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/31\">",
"      Ozols J, Korza G, Heinemann FS, et al. Complete amino acid sequence of steer liver microsomal NADH-cytochrome b5 reductase. J Biol Chem 1985; 260:11953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/32\">",
"      Yubisui T, Miyata T, Iwanaga S, et al. Complete amino acid sequence of NADH-cytochrome b5 reductase purified from human erythrocytes. J Biochem 1986; 99:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/33\">",
"      Page DH, El-Hosseiny F, Winkler K. Behaviour of single wood fibres under axial tensile strain. Nature 1971; 229:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/34\">",
"      Kitajima S, Yasukochi Y, Minakami S. Purification and properties of human erythrocyte membrane NADH-cytochrome b5 reductase. Arch Biochem Biophys 1981; 210:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/35\">",
"      Francois. A case of congenital cyanosis without an apparent cause. Bull Acad Roy Med Belg 1845; 4:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/36\">",
"      Hitzenberger K. Autotoxic cyanosis due to intraglobular methemoglobinemia. Wien Arch Med 1932; 23:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/37\">",
"      Gibson QH. Historical note: methemoglobinemia--long ago and far away. Am J Hematol 1993; 42:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/38\">",
"      Percy MJ, Gillespie MJ, Savage G, et al. Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. Blood 2002; 100:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/39\">",
"      Gibson Q. Introduction: congenital methemoglobinemia revisited. Blood 2002; 100:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/40\">",
"      Dekker J, Eppink MH, van Zwieten R, et al. Seven new mutations in the nicotinamide adenine dinucleotide reduced-cytochrome b(5) reductase gene leading to methemoglobinemia type I. Blood 2001; 97:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/41\">",
"      Board PG, Pidcock ME. Methaemoglobinaemia resulting from heterozygosity for two NADH-methaemoglobin reductase variants: characterization as NADH-ferricyanide reductase. Br J Haematol 1981; 47:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/42\">",
"      Gonz&aacute;lez R, Estrada M, Wade M, et al. Heterogeneity of hereditary methaemoglobinaemia: a study of 4 Cuban families with NADH-Methaemoglobin reductase deficiency including a new variant (Santiago de Cuba variant). Scand J Haematol 1978; 20:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/43\">",
"      Jaffe E. Hereditary methemoglobinemias associated with abnormalities in the metabolism of erythrocytes. Am J Med 1962; 32:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/44\">",
"      Waller HD. Inherited methemoglobinemia (enzyme deficiencies). Humangenetik 1970; 9:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/45\">",
"      Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med 1968; 279:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/46\">",
"      SCOTT EM, HOSKINS DD. Hereditary methemoglobinemia in Alaskan Eskimos and Indians. Blood 1958; 13:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/47\">",
"      SCOTT EM. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia. J Clin Invest 1960; 39:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/48\">",
"      BALSAMO P, HARDY WR, SCOTT EM. HEREDITARY METHEMOGLOBINEMIA DUE TO DIAPHORASE DEFICIENCY IN NAVAJO INDIANS. J Pediatr 1964; 65:928.",
"     </a>",
"    </li>",
"    <li>",
"     Andreeva A, Dmitrieva M, Levina A, et al. Molecular basis for disorders in the functional properties of hemoglobin in patients with enzymopenic methemoglobinemia. In: Papers of the 49th Scientific Session of the Central Scientific Research Institute of Hematology and Blood Tra, 1979. p.73.",
"    </li>",
"    <li>",
"     Ilinskaia, I, Derviz, et al. Enzymatic methemoglobinemia. In: Papers of the symposium: Biological problems of the north, State University, Yakutsk, 1974. p.226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/51\">",
"      Prchal JT, Borgese N, Moore MR, et al. Congenital methemoglobinemia due to methemoglobin reductase deficiency in two unrelated American black families. Am J Med 1990; 89:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/52\">",
"      Shirabe K, Yubisui T, Borgese N, et al. Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). J Biol Chem 1992; 267:20416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/53\">",
"      Katsube T, Sakamoto N, Kobayashi Y, et al. Exonic point mutations in NADH-cytochrome B5 reductase genes of homozygotes for hereditary methemoglobinemia, types I and III: putative mechanisms of tissue-dependent enzyme deficiency. Am J Hum Genet 1991; 48:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/54\">",
"      Jenkins MM, Prchal JT. A novel mutation found in the 3' domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 1996; 87:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/55\">",
"      Jenkins MM, Prchal JT. A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. Hum Genet 1997; 99:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/56\">",
"      Leroux A, Junien C, Kaplan J, Bamberger J. Generalised deficiency of cytochrome b5 reductase in congenital methaemoglobinaemia with mental retardation. Nature 1975; 258:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/57\">",
"      Takeshita M, Tamura M, Kugi M, et al. Decrease of palmitoyl-CoA elongation in platelets and leukocytes in the patient of hereditary methemoglobinemia associated with mental retardation. Biochem Biophys Res Commun 1987; 148:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/58\">",
"      Prchal J. Hemoglobins continue to fascinate and surprise. The Hematologist 2006; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/59\">",
"      Vieira LM, Kaplan JC, Kahn A, Leroux A. Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. Blood 1995; 85:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/60\">",
"      Shirabe K, Landi MT, Takeshita M, et al. A novel point mutation in a 3' splice site of the NADH-cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. Am J Hum Genet 1995; 57:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/61\">",
"      Jenkins MM, Prchal JT. A novel mutation found in the 3' domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 1996; 87:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/62\">",
"      Kobayashi Y, Fukumaki Y, Yubisui T, et al. Serine-proline replacement at residue 127 of NADH-cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type. Blood 1990; 75:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/63\">",
"      Manabe J, Arya R, Sumimoto H, et al. Two novel mutations in the reduced nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase gene of a patient with generalized type, hereditary methemoglobinemia. Blood 1996; 88:3208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/64\">",
"      Shirabe K, Fujimoto Y, Yubisui T, Takeshita M. An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. J Biol Chem 1994; 269:5952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/65\">",
"      Owen EP, Berens J, Marinaki AM, et al. Recessive congenital methaemoglobinaemia type II a new mutation which causes incorrect splicing in the NADH-cytochrome b5 reductase gene. J Inherit Metab Dis 1997; 20:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/66\">",
"      Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol 1993; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     Beutler, E. Methemoglobinemia and other causes of cyanosis. In: Williams' Hematology, 5th ed, Beutler, E, Lichtman, MA, Coller, B, Kipps, TJ (Eds), McGraw-Hill, New York, 1995, p. 654.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/68\">",
"      Crowley MA, Mollan TL, Abdulmalik OY, et al. A hemoglobin variant associated with neonatal cyanosis and anemia. N Engl J Med 2011; 364:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/69\">",
"      Hackett CS, Strittmatter P. Covalent cross-linking of the active sites of vesicle-bound cytochrome b5 and NADH-cytochrome b5 reductase. J Biol Chem 1984; 259:3275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/70\">",
"      Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med 1986; 314:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/71\">",
"      Giordano SJ, Kaftory A, Steggles AW. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994; 93:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/72\">",
"      TOWNES PL, MORRISON M. Investigation of the defect in a variant of hereditary methemoglobinemia. Blood 1962; 19:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/73\">",
"      Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/74\">",
"      Daly JS, Hultquist DE, Rucknagel DL. Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase. J Med Genet 1983; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/75\">",
"      Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore) 2004; 83:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/76\">",
"      Falkenhahn M, Kannan S, O'Kane M. Unexplained acute severe methaemoglobinaemia in a young adult. Br J Anaesth 2001; 86:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/77\">",
"      Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med 2004; 164:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/78\">",
"      Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors. Arch Intern Med 2007; 167:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/79\">",
"      Henry LR, Pizzini M, Delarso B, Ridge JA. Methemoglobinemia: early intraoperative detection by clinical observation. Laryngoscope 2004; 114:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/80\">",
"      Eng LI, Loo M, Fah FK. Diaphroase activity and variants in normal adults and newborns. Br J Haematol 1972; 23:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/81\">",
"      Bartos HR, Desforges JF. Erythrocyte DPNH dependent diaphorase levels in infants. Pediatrics 1966; 37:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/82\">",
"      ROSS JD. Deficient activity of DPNH-dependent methemoglobin diaphorase in cord blood erythrocytes. Blood 1963; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/83\">",
"      Yano SS, Danish EH, Hsia YE. Transient methemoglobinemia with acidosis in infants. J Pediatr 1982; 100:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/84\">",
"      HEYMAN I. Methemoglobinemia in infants. Harefuah 1954; 46:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/85\">",
"      Hegesh E, Shiloah J. Blood nitrates and infantile methemoglobinemia. Clin Chim Acta 1982; 125:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/86\">",
"      Pollack ES, Pollack CV Jr. Incidence of subclinical methemoglobinemia in infants with diarrhea. Ann Emerg Med 1994; 24:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/87\">",
"      Hanukoglu A, Danon PN. Endogenous methemoglobinemia associated with diarrheal disease in infancy. J Pediatr Gastroenterol Nutr 1996; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/88\">",
"      Comly H. Cyanosis in infants caused by nitrates in well water. JAMA 1945; 129:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/89\">",
"      Kross BC, Ayebo AD, Fuortes LJ. Methemoglobinemia: nitrate toxicity in rural America. Am Fam Physician 1992; 46:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/90\">",
"      Greer FR, Shannon M, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Committee on Environmental Health. Infant methemoglobinemia: the role of dietary nitrate in food and water. Pediatrics 2005; 116:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4841/abstract/91\">",
"      Knobeloch L, Saina B, Hogan A, et al. Blue babies and nitrate-contaminated well water. Environ Health Perspect 2011; 108:675.",
"     </a>",
"    </li>",
"    <li>",
"     Fact sheet for nitrates and nitrites: file://www.atsdr.cdc.gov/toxfaqs/tf.asp?id=1186&amp;tid=258 (Accessed on December 15, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7093 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4841=[""].join("\n");
var outline_f4_46_4841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11590453\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHEMOGLOBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cytochrome b5 reductase pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - NADPH-methemoglobin reductase pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antioxidant protein 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CYTOCHROME B5 REDUCTASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Isoforms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THE HEREDITARY METHEMOGLOBINEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cytochrome b5 reductase 3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemoglobin M disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cytochrome b5 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11590826\">",
"      ACQUIRED/ACUTE TOXIC METHEMOGLOBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590834\">",
"      Drugs and exogenous agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590841\">",
"      Topical anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590848\">",
"      Infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3816429\">",
"      - Contaminated well water",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11590453\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590554\">",
"      Formation of methemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590561\">",
"      Hereditary methemoglobinemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11590576\">",
"      Acquired methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/8/24718\" title=\"figure 2\">",
"      Methemoglobin reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/28/39372\" title=\"table 1\">",
"      Agents causing methemoglobinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=related_link\">",
"      Transesophageal echocardiography: Indications, complications, and normal views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_46_4842="Early gastric cancer: Treatment, natural history, and prognosis";
var content_f4_46_4842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early gastric cancer: Treatment, natural history, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Douglas Morgan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/46/4842/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/46/4842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H762443442\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early gastric cancer (EGC) is defined as invasive gastric cancer that invades no more deeply than the submucosa, irrespective of lymph node metastasis (T1, any N). While EGC is of particular importance for patient care in Eastern Asia, its significance extends to other disciplines and patient populations. Early gastric cancer has driven the development of novel imaging technologies (eg, magnification chromoendoscopy and narrow-band imaging) as well as advanced endoscopic resection techniques (eg, endoscopic mucosal resection and endoscopic submucosal dissection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link&amp;anchor=H5#H5\">",
"     \"Magnification endoscopy\", section on 'Stomach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the treatment as well as the natural history and prognosis of early gastric cancer. The clinical manifestations, diagnosis, and staging of early gastric cancer and the management of patients with advanced gastric cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19333?source=see_link\">",
"     \"Local palliation for advanced gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935963\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment modalities for early gastric cancer (EGC) include endoscopic resection, surgery (gastrectomy), antibiotic treatment for eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    , and adjuvant therapies. Endoscopic resection, by either endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), is an option for carefully selected patients with EGC without known lymph node involvement who meet specific criteria (ie, have a sufficiently low risk for nodal metastases that endoscopic resection alone is likely to be curative). Patients who do not meet the criteria are referred for gastrectomy (which includes resection of the regional nodes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Extent of lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proper staging is crucial for determining which patients are potential candidates for endoscopic resection. The staging of early gastric cancer, including the evaluation of regional lymph nodes for metastatic disease, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H2083142#H2083142\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients, regardless of approach, should be evaluated for",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and treated if there is evidence of infection. (See",
"    <a class=\"local\" href=\"#H757936026\">",
"     'Anti-Helicobacter therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935970\">",
"    <span class=\"h2\">",
"     Endoscopic therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935977\">",
"    <span class=\"h3\">",
"     Standard and expanded criteria for endoscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general guidelines for the selection of patients with EGC who are appropriate for endoscopic resection with EMR or ESD are outlined below [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High probability of en bloc resection",
"     </li>",
"     <li>",
"      Tumor histology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intestinal type adenocarcinoma",
"     </li>",
"     <li>",
"      Tumor confined to the mucosa",
"     </li>",
"     <li>",
"      Absence of venous or lymphatic invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor size and morphology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 20 mm in diameter, without ulceration",
"     </li>",
"     <li>",
"      Less than 10 mm in diameter if Paris classification IIb or IIc (",
"      <a class=\"graphic graphic_table graphicRef50239 \" href=\"UTD.htm?12/56/13195\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Expansion of the criteria has been proposed by centers in Eastern Asia, although this is not a standard approach and is best considered an area of active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed expanded criteria for endoscopic resection of intestinal type EGC are [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucosal tumors of any size without ulceration",
"     </li>",
"     <li>",
"      Mucosal tumors less than 30 mm with ulceration",
"     </li>",
"     <li>",
"      Submucosal tumors less than 30 mm confined to the upper 0.5 mm of the submucosa without lymphovascular invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients meeting the expanded criteria are at lower risk of lymph node metastases than those who do not meet them, although patients meeting expanded criteria are at an increased risk of lymph node metastases compared with those who meet standard criteria (2 versus 4 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. For patients who meet these expanded criteria, and wish to avoid surgery, removal of the tumor using ESD (rather than EMR) is generally preferred because ESD is able to achieve a deeper resection margin. (See",
"    <a class=\"local\" href=\"#H757935998\">",
"     'Endoscopic submucosal dissection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H711582#H711582\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Lymph node metastases in EGC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, general indications for gastrectomy with removal of perigastric lymph nodes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low probability of en bloc resection with EMR or ESD (ie, the endoscopic resection would be piecemeal)",
"     </li>",
"     <li>",
"      Diffuse rather than intestinal type adenocarcinoma",
"     </li>",
"     <li>",
"      Submucosal tumor size greater than 30 mm, or ulcerated tumors",
"     </li>",
"     <li>",
"      Evidence of lymphovascular (lymphatic or venous) invasion in the primary tumor, or",
"      <span class=\"nowrap\">",
"       known/suspected",
"      </span>",
"      regional lymph node metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935984\">",
"    <span class=\"h3\">",
"     Endoscopic mucosal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;EMR is an alternative to surgery that was first introduced in 1978. Where available, EMR is often the procedure of choice for patients who meet the standard criteria for endoscopic resection of an EGC. Technical aspects related to EMR are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H757935977\">",
"     'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'ER Techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153456916\">",
"    <span class=\"h4\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown high survival and cure rates in patients with EGC who undergo EMR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early series with 308 patients with EGC, EMR successfully eradicated the cancer in 85 percent of patients, with five-year survival rates of 86 percent, values that approached gastrectomy outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/8\">",
"       8",
"      </a>",
"      ]. The complete endoscopic resection rate was lower (approximately 50 percent) with type IIa lesions larger than 2 cm and with type IIc lesions that were either larger than 1 cm or were associated with undifferentiated adenocarcinoma (",
"      <a class=\"graphic graphic_table graphicRef71003 \" href=\"UTD.htm?18/35/19003\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a second series that included 76 lesions in patients with absolute indications for treatment, 53 of the lesions (70 percent) were completely resected by EMR [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/9\">",
"       9",
"      </a>",
"      ]. Laser irradiation or heater probe cautery was used to treat 22 of the 23 incompletely resected lesions. Among the 53 lesions that were complete resected, there was one recurrence (2 percent) and the overall cure rate for those with follow-up was 98 percent (48 of 49 patients). Among the 22 lesions treated with additional therapy for an incomplete resection, there was one recurrence (5 percent). The overall cure rate in this group was 96 percent (21 of 22 patients).",
"     </li>",
"     <li>",
"      In a Japanese report of 131 patients with differentiated mucosal EGC less than 2 cm, the 5- and 10-year overall survival rates were 84 and 64 percent, respectively. The disease-specific survival rates at both 5- and 10-year follow-up were 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one of the larger series from the West that included 39 patients in Germany with small tumors considered to be at low risk of recurrence, 97 percent of patients achieved remission after initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/11\">",
"       11",
"      </a>",
"      ]. However, recurrent or metachronous lesions developed in 11 patients (29 percent) during a mean of 57 months of follow-up; all were treated successfully with repeat endoscopic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of EMR include bleeding and perforation, though in experienced hands, EMR is a safe procedure that can be performed on outpatients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H1942073#H1942073\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935991\">",
"    <span class=\"h4\">",
"     Management of incomplete resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of endoscopic therapy is en bloc resection, but incomplete resection remains a challenge and there is no definitive standard for managing patients with incomplete resections. Typically, gastrectomy has been recommended for patients with incomplete resections, especially for tumors with positive vertical margins, and for those with submucosal involvement or lymphovascular invasion. However, repeat endoscopic resection may be considered in selected patients who are poor surgical candidates. In a single center study in Korea of 159 patients endoscopically treated between 1994 and 2009 without additional treatment, three- and five-year survival rates were 83 and 77 percent, respectively, with lower rates for those with lymphovascular invasion (62 and 42 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As suggested by the high survival rates, not all patients with tumor-positive resection margins will have residual tumor or tumor recurrence. In a study of 102 Korean patients with positive lateral or vertical resection margins, residual tumor was detected in 17 of 46 (37 percent) of those who underwent immediate additional endoscopic or surgical resection; tumor recurrence was seen in 17 of 56 (30 percent) who did not undergo immediate therapy but were followed endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/13\">",
"     13",
"    </a>",
"    ]. On multivariable analysis, the only independent risk factor for residual",
"    <span class=\"nowrap\">",
"     tumor/tumor",
"    </span>",
"    recurrence was the length of the lateral resection margin with tumor involvement.",
"   </p>",
"   <p>",
"    The best way to manage patients with only positive lateral margins after EMR is controversial. In a study of 726 patients treated by EMR between 1991 and 2000, 348 (48 percent) had incomplete resections, 309 (89 percent) of whom had only positive lateral margins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/14\">",
"     14",
"    </a>",
"    ]. Of these 309 patients, 288 (93 percent) were followed endoscopically (with or without additional endoscopic treatment) with no recurrences. Among the remaining 21 patients who underwent gastrectomy, none had positive lymph nodes. Of the 39 patients in the higher-risk group (positive vertical margins or",
"    <span class=\"nowrap\">",
"     submucosal/lymphovascular",
"    </span>",
"    invasion), 24 underwent gastrectomy. In this group, four patients (17 percent) had positive lymph nodes at surgery.",
"   </p>",
"   <p>",
"    This case series suggests that patients with positive lateral margins but without positive vertical margins, submucosal invasion, or lymphovascular invasion can be managed with further endoscopic therapy, without gastrectomy.",
"   </p>",
"   <p>",
"    Assessing the completeness of resection is more difficult in patients who have their tumors removed piecemeal compared with those who have an en bloc resection, and patients undergoing piecemeal resection are at increased risk of recurrence. In a 10-year follow-up study of 149 patients with EGC who underwent EMR in Japan, the tumors were removed en bloc in 66 cases and piecemeal in 83 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/15\">",
"     15",
"    </a>",
"    ]. The mean tumor size was significantly larger in the patients who had piecemeal resections (21 versus 17 mm). Two of the patients who had en bloc resections had subsequent surgery because tumor was clearly present at the resection margin. None of the patients with an en bloc resection had a recurrence. Of the patients with piecemeal resections, nine underwent surgery for clearly positive margins. Recurrences were noted in 21 of the 74 patients (28 percent) who did not undergo surgery following piecemeal resection and were more common among those with unclear lateral margins (adjusted hazard ratio 1.6 [95% CI, 1.1-2.4]). The recurrences were treated with surgery (eight patients) or with additional endoscopic therapy (13 patients). Despite the 28 percent recurrence rate in patients who underwent piecemeal resection, there were no deaths due to gastric cancer during the 10-year follow-up period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757935998\">",
"    <span class=\"h3\">",
"     Endoscopic submucosal dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, larger tumors are at higher risk of requiring piecemeal resection with EMR, which is associated with higher recurrence rates. ESD permits en bloc resection of larger tumors than can be treated with EMR [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/16-23\">",
"     16-23",
"    </a>",
"    ], and also permits a deeper resection margin in patients with submucosal involvement who are candidates for endoscopic resection. ESD has also been combined with laparoscopic sentinel lymph dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H757935977\">",
"     'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With ESD, various types of endoscopic electrosurgical needle knives are used to incise mucosa surrounding the tumor. The mucosa is subsequently dissected away from the underlying submucosa, and the entire tumor is removed en bloc. ESD is more technically challenging than EMR and, for the most part, ESD is performed in high-volume referral centers. While the technique has shown promise in highly experienced hands, complications including bleeding and perforation have been described. English-language publications that included &gt;300 ESD cases suggest that important complications include: perforation (1 to 5 percent), delayed perforation (0.5 percent), delayed bleeding (0 to 16 percent), stenosis (0.7 to 2 percent overall, with rates up to 17 and 7 percent for cardia and peri-pyloric resections, respectively), and aspiration pneumonia (0.8 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'ESD techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete resection rates may be higher with ESD than with EMR. In a retrospective study of 896 patients with 1020 EGCs conducted in Japan, 825 lesions were treated with EMR and 195 were treated by ESD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/18\">",
"     18",
"    </a>",
"    ]. Mean tumor size did not differ between those treated with EMR and those treated with ESD (15 versus 19 mm). The majority of lesions removed with EMR were removed piecemeal (58 percent), whereas the majority of lesions removed with ESD were removed en bloc (83 percent). Complete resection rates were lower in patients treated with EMR compared with those treated with ESD (24 versus 83 percent). The patients treated with EMR were followed for a mean of 83 months. Local recurrence developed in 1 of 195 patients with a complete resection following EMR (0.5 percent), whereas local recurrences developed in 30 of 630 patients with incomplete resections (5 percent). There were no local recurrences in the patients treated with ESD during a mean follow-up of 19 months.",
"   </p>",
"   <p>",
"    However, while there were no recurrences in the 33 patients in the above study who had an incomplete resection following ESD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/18\">",
"     18",
"    </a>",
"    ], gastrectomy should be considered for patients who are surgical candidates and who have residual cancer present at the lateral or vertical resection margins following ESD. This was illustrated in a study that examined 118 patients who underwent gastrectomy following incomplete ESD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/26\">",
"     26",
"    </a>",
"    ]. ESD was considered incomplete if there was residual cancer at the ESD margin, invasion of the submucosa or muscularis propria by tumor, lymphatic invasion, or an undifferentiated cell type. A total of 27 patients (23 percent) had residual cancer at the ESD margin, and 29 patients (25 percent) had residual cancer in the gastrectomy specimen. Patients with a tumor present at the lateral margin of the ESD specimen had a particularly high rate of residual tumor (63 percent, hazard ratio 13 [95% CI, 3.8, 44]). (See",
"    <a class=\"local\" href=\"#H757935984\">",
"     'Endoscopic mucosal resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies have looked at performing laparoscopic lymph node dissection in patients with negative margins but incomplete resections based upon other factors (eg, undifferentiated adenocarcinoma, presence of lymphovascular invasion, presence of submucosal invasion). Currently, gastrectomy with removal of perigastric lymph nodes is recommended for such patients, but small studies suggest that laparoscopic lymph node dissection may be a reasonable alternative.",
"   </p>",
"   <p>",
"    In a study of 21 patients with negative margins but with incomplete resections based upon other factions, lymph node dissection revealed lymph node metastases in two patients (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/27\">",
"     27",
"    </a>",
"    ]. The area chosen for lymph node dissection was based upon the location of the tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lymphatic drainage of the stomach visualized with standard laparoscopy or with infrared ray electronic laparoscopy following submucosal injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    around post-ESD scars. The patients with lymph node metastases were offered gastrectomy, but declined additional treatment. There were no local recurrences in any of the 21 patients during a median follow-up of 61 months, though two patients developed metachronous EGCs and were again treated with ESD.",
"   </p>",
"   <p>",
"    In a similar study of five patients, one patient was found to have lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/28\">",
"     28",
"    </a>",
"    ]. The patient elected not to undergo any additional treatment and was free of recurrence at 14 months follow-up. In addition, no recurrences were noted in any of the patients with negative lymph nodes after 11 to 37 months follow-up.",
"   </p>",
"   <p>",
"    These studies suggest that patients with incomplete resections but with negative margins following ESD do well with lymph node dissection without gastrectomy. However, given the small numbers of patients studied, until more data become available, the standard of care for patients with incomplete resections remains gastrectomy with removal of perigastric lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936005\">",
"    <span class=\"h3\">",
"     Endoscopic resection versus gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection can be used for the treatment of patients meeting appropriate criteria in areas with appropriate resources. However, worldwide, gastrectomy remains the most widely used approach for the treatment of EGC.",
"   </p>",
"   <p>",
"    There are no randomized trials comparing endoscopic versus surgical management of EGC. The limited data comparing outcomes in patients treated with endoscopic resection with those treated with gastrectomy suggest similar clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a matched cohort study, there were no differences between the treatments with regard to mortality, recurrence rates, or complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/29\">",
"     29",
"    </a>",
"    ]. However, patients treated with EMR had a higher risk of metachronous gastric cancers, though all were successfully treated. Patients in the EMR group had shorter median hospital stays (8 versus 15 days) and lower costs of care ($2049 versus $4042).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936012\">",
"    <span class=\"h3\">",
"     Other endoscopic modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other endoscopic modalities have been investigated but do not have an established role in the treatment of EGC. These include photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], Nd:YAG laser treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], and argon plasma coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link&amp;anchor=H2#H2\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\", section on 'Technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link&amp;anchor=H18438655#H18438655\">",
"     \"Basic principles of medical lasers\", section on 'Solid state'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link&amp;anchor=H2#H2\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\", section on 'What is APC?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, 27 patients with EGC were treated with the photosensitizer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    (Photofrin II). Their tumors were then exposed to an argon laser [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/31\">",
"     31",
"    </a>",
"    ]. A complete response to therapy was observed in 88 percent. An important caveat is that these therapies are considered \"tissue-destroying\" therapies, without available pathology specimens for examination, whereas EMR and ESD are \"tissue-retrieving\" therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936019\">",
"    <span class=\"h2\">",
"     Gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection can be used for the treatment of patients meeting appropriate criteria in countries with a high incidence of EGC and appropriate resources. However, worldwide, gastrectomy remains the most widely used approach for the treatment of EGC. Gastrectomy is associated with five-year survival rates of up to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study with 304 patients who underwent pylorus-preserving gastrectomy for EGC, the five-year survival rate was 98 percent, and there was no gastric cancer-related mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Japanese series with 611 patients with EGC in the middle third of the stomach, a pylorus-preserving gastrectomy was associated with an overall five-year survival rate of 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/39\">",
"       39",
"      </a>",
"      ]. The most common complication was gastric stasis (8 percent), and major complications included leaks and abscesses (3 percent overall).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastrectomy is recommended for patients who do not fulfill the criteria for endoscopic resection or if providers with appropriate endoscopic expertise are not available. Patients who do not fulfill the criteria for endoscopic resection are at increased risk of lymph node metastases and should have a gastrectomy with removal of perigastric lymph nodes. (See",
"    <a class=\"local\" href=\"#H757935977\">",
"     'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, gastrectomy should be performed for patients with lymph node involvement detected or highly suspected during preoperative staging to remove both the tumor and the lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H711436#H711436\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Staging workup'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Either subtotal or total gastrectomy is performed, depending upon the tumor location [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/45-52\">",
"     45-52",
"    </a>",
"    ]. A total gastrectomy is usually performed for lesions in the upper third of the stomach, and subtotal gastrectomy for lesions in the lower two-thirds [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=see_link\">",
"     \"Invasive gastric cancer: Surgery and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26621863\">",
"    <span class=\"h3\">",
"     Laparoscopic gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least five randomized trials have directly compared laparoscopic versus open gastrectomy for early gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest multicenter trial, in which 342 patients with early gastric cancer were randomly assigned to open gastrectomy or laparoscopic-assisted distal gastrectomy, reported less intraoperative bleeding in the laparoscopic group but similar postoperative complication rates (10.5 and 14.7 percent for laparoscopic and open procedures, respectively), postoperative mortality rates (1.1 versus 0 percent), and extent of lymph node dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/56\">",
"       56",
"      </a>",
"      ]. However, median follow-up was insufficient to assess oncologic outcomes.",
"     </li>",
"     <li>",
"      The second largest randomized trial, enrolling 164 patients, only reported outcomes at a median follow-up of 12 months and thus was also unable to address long-term oncologic outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The other three trials all enrolled less than 50 patients each, and none reported long-term follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/53,55,57\">",
"       53,55,57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of these five randomized trials plus 18 non-randomized comparisons of laparoscopic versus open gastrectomy (22 studies, 3411 participants) came to the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean number of lymph nodes retrieved by laparoscopic surgery was close to that retrieved during an open procedure.",
"     </li>",
"     <li>",
"      The conversion rate from laparoscopic to open surgery was between 0 and 3 percent.",
"     </li>",
"     <li>",
"      There was significantly less postoperative morbidity after a laparoscopic procedure (relative risk 0.58, 95% CI, 0.46-0.74).",
"     </li>",
"     <li>",
"      Laparoscopic surgery reduced intraoperative blood loss, postoperative analgesic consumption, and length of hospital stay without increasing total hospital costs or cancer recurrence rates.",
"     </li>",
"     <li>",
"      Long-term survival of laparoscopically treated patients was similar to that of patients undergoing open surgery.",
"     </li>",
"     <li>",
"      The quality of the evidence supporting the above conclusions was generally very low, particularly for the outcomes of cancer recurrence and long-term survival. There were very few recurrence events reported (39), and only two studies (totaling 353 patients) reported five-year overall survival rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, laparoscopic distal gastrectomy may represent a technically feasible alternative for early gastric cancer when it is performed in experienced centers. However, additional data from methodologically high-quality comparative trials with long-term follow-up are needed before it can be confidently concluded that oncologic outcomes are comparable to those obtained by open gastrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936026\">",
"    <span class=\"h2\">",
"     Anti-Helicobacter therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for",
"    <em>",
"     H. pylori",
"    </em>",
"    infection is recommended because",
"    <em>",
"     H. pylori",
"    </em>",
"    infection is a well-defined risk factor for both early and invasive gastric cancer, and chronic infection is associated with tumor recurrence. In addition, the treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    decreases the risk of developing gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] and decreases the risk of recurrence following treatment for gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial and a case series both found that eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    following endoscopic resection of EGC reduced the risk of metachronous cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The randomized trial included 544 patients with EGC who were treated with endoscopic resection. Patients were assigned to either receive standard triple therapy for",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication or standard of care without eradication. Patients in the",
"    <em>",
"     H. pylori",
"    </em>",
"    treatment arm had a lower risk of metachronous gastric cancer at the three-year time point compared with those in the control arm (odds ratio 0.35; 95% CI, 0.16-0.78).",
"   </p>",
"   <p>",
"    However, whether the lower risk of cancer is sustained long-term is not clear. A retrospective study examined 268 patients who were",
"    <em>",
"     H. pylori",
"    </em>",
"    positive and had undergone endoscopic resection for EGC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/63\">",
"     63",
"    </a>",
"    ].",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication was achieved in 177 patients, whereas 91 had persistent infection. Patients were followed up to 11 years (median 3 years). By the end of the study, metachronous cancer had developed in 9 percent of the eradicated patients and in 14 percent of the patients with persistent infection, although the difference was not statistically significant.",
"   </p>",
"   <p>",
"    Given the decreased rate of metachronous cancer in the randomized trial, we recommend that all patients with EGC, regardless of the therapeutic approach, be evaluated for",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and treated if positive. In the event of negative biopsies for",
"    <em>",
"     H. pylori",
"    </em>",
"    , infection status should be determined with serology, as",
"    <em>",
"     H. pylori",
"    </em>",
"    organism loads may decrease with the onset of precancerous lesions and adenocarcinoma, thereby affecting biopsy sensitivity. Any patient with positive serology who does not have a history of having been treated for",
"    <em>",
"     H. pylori",
"    </em>",
"    should receive treatment, even if biopsies are negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936033\">",
"    <span class=\"h2\">",
"     Adjuvant therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant therapy, either with systemic chemotherapy, radiotherapy, or intraperitoneal chemotherapy for patients who have undergone complete endoscopic resection of EGC is not clearly established, especially for patients with node-negative disease. The 2011 consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    (NCCN) recommend observation without adjuvant therapy for patients with Tis or T1, N0 disease who have uninvolved resection margins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/64\">",
"     64",
"    </a>",
"    ]. On the other hand, adjuvant therapy is recommended for all patients with positive lymph nodes, regardless of T stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/38/11882?source=see_link\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936040\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936047\">",
"    <span class=\"h2\">",
"     Prognosis without treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early report from Japan suggested that without treatment, 63 percent of patients with early gastric cancer (EGC) will progress to advanced stage disease within five years (6 to 88 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/65\">",
"     65",
"    </a>",
"    ]. EGC may represent a meta-stable biologic state, with doubling times on the order of several years, versus advanced cancer with doubling times of less than a year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936054\">",
"    <span class=\"h2\">",
"     Prognosis following treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall five-year survival rate for treated EGC in most modern era series is over 90 percent: nearly 100 percent for mucosal tumors, and 80 to 90 percent for submucosal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. The recurrence rate after surgery is approximately 2 to 5 percent in reports from Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/71\">",
"     71",
"    </a>",
"    ] and Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/9\">",
"     9",
"    </a>",
"    ] and 5 to 15 percent in studies from Western centers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/72\">",
"     72",
"    </a>",
"    ]. These recurrence rates partially reflect differences in length of follow-up, but may also be due to differences in the pathologic diagnosis of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H757935984\">",
"     'Endoscopic mucosal resection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H757936019\">",
"     'Gastrectomy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H3#H3\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Histologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Synchronous and metachronous gastric cancers are common in patients with EGC. In a Japanese series, 58 of 633 patients (9.2 percent) with EGCs had synchronous cancers, defined as a second cancer found within the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/74\">",
"     74",
"    </a>",
"    ]. In long-term follow-up, the overall incidence of metachronous cancers was 8.2 percent, the majority of which were able to be resected endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/74\">",
"     74",
"    </a>",
"    ]. This was echoed in a Korean retrospective study of 602 patients treated with ESD over 4.5 years, wherein 2 percent had synchronous advanced gastric lesions (7 adenocarcinomas, 5 adenomas with dysplasia) that were not detected during the initial evaluation, underscoring the importance of careful endoscopic inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/75\">",
"     75",
"    </a>",
"    ]. In patients who have undergone partial gastrectomy, late recurrences or metachronous lesions occur in the gastric remnant in approximately 2 to 8 percent of cases of EGC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/46,76,77\">",
"     46,76,77",
"    </a>",
"    ]. A nomogram has been developed to predict disease free-survival (",
"    <a class=\"graphic graphic_figure graphicRef74583 \" href=\"UTD.htm?36/53/37726\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936061\">",
"    <span class=\"h2\">",
"     Prognosis with lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EGC literature suggests that 2 to 3 percent of mucosal EGCs and 20 to 30 percent of submucosal EGCs will have lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/1,79-81\">",
"     1,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of lymph node involvement in EGC has been illustrated in several studies of patients who have undergone gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/51,76,82,83\">",
"     51,76,82,83",
"    </a>",
"    ]. In a Korean study, long-term survival was 95 percent in patients with no lymph node involvement, 88 percent in those with one to three nodes involved, and 77 percent in those with more than three nodes involved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar results have been seen in other series. A large retrospective multicenter Italian study in patients with EGC reported long-term survival after surgical resection of 92, 82, 73, and 27 percent for patients with 0, 1 to 3, 4 to 6, and &gt;6 positive nodes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/82\">",
"     82",
"    </a>",
"    ]. Another series retrospectively evaluated 621 patients with EGC who underwent gastrectomy with lymphadenectomy between 1966 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/76\">",
"     76",
"    </a>",
"    ]. Lymph node metastases were observed in 10 percent of cases, and the median follow-up was 123 months. Recurrence during follow-up was much lower in those without nodal involvement (1.8 versus 9.5 percent). As in other studies, the risk of lymph node metastasis increased significantly with submucosal invasion and greater tumor size [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/76,84,85\">",
"     76,84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757936068\">",
"    <span class=\"h1\">",
"     POST-TREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to guide surveillance strategies following remission from early gastric cancer. The 2011 consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    (NCCN) suggest the same follow-up strategy as used for more advanced disease, regardless of treatment type [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History and physical examination every three to six months for years one to two, every 6 to 12 months for years three to five, and then annually",
"     </li>",
"     <li>",
"      Complete blood count and chemistry profile as indicated",
"     </li>",
"     <li>",
"      Radiologic imaging or endoscopy as clinically indicated",
"     </li>",
"     <li>",
"      Monitor for nutritional deficiency in surgically resected patients and treat as indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that performing endoscopy sooner than three months following resection is of limited benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/87\">",
"     87",
"    </a>",
"    ]. Our practice is to perform surveillance endoscopies annually.",
"   </p>",
"   <p>",
"    Surveillance endoscopies permit endoscopic treatment of cancers that may have been missed during the initial endoscopic resection or that subsequently developed. The use of routine surveillance endoscopy is supported by a multicenter retrospective cohort study from Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/46/4842/abstract/88\">",
"     88",
"    </a>",
"    ]. The study included 1258 patients who underwent endoscopic submucosal dissection (ESD) for early gastric cancer. Following ESD, patients underwent surveillance endoscopy every 6 to 12 months. During a median follow-up of 27 months, synchronous (occurring within one year of ESD) or metachronous (after one year) cancers were detected in 175 patients (14 percent), and local recurrence was detected in five patients (0.4 percent). One hundred sixty-four of the synchronous and metachronous cancers (94 percent) were successfully treated with repeat ESD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/28/32195?source=see_link\">",
"       \"Patient information: Stomach cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757938171\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early gastric cancer (EGC) is defined as adenocarcinoma limited to the gastric mucosa or submucosa, regardless of involvement of the regional lymph nodes (T1, any N). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H1#H1\">",
"       \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that patients with known or suspected lymph node metastases be referred for gastrectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Gastrectomy with removal of perigastric lymph nodes permits the evaluation and removal of involved lymph nodes, which is important because lymph node metastases are associated with tumor recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H711582#H711582\">",
"       \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Lymph node metastases in EGC'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H757936019\">",
"       'Gastrectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H757936061\">",
"       'Prognosis with lymph node involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without suspected lymph node involvement who meet the standard or expanded criteria for endoscopic resection, we suggest endoscopic resection rather than gastrectomy, provided that there is local expertise in the endoscopic resection techniques (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is imperative that a thorough evaluation for involved lymph nodes be performed prior to therapy to determine if endoscopic resection is an appropriate treatment option. This is often done with endoscopic ultrasound. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link&amp;anchor=H10#H10\">",
"       \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\", section on 'Endoscopic ultrasonography'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endoscopic resection is associated with less treatment-related morbidity than gastrectomy and the available data suggest similar outcomes for",
"      <strong>",
"       appropriately selected",
"      </strong>",
"      patients with EGC when the procedure is performed by individuals experienced in endoscopic resection. Such expertise is less common in the United States compared with Asia. However, comparisons of endoscopic resection with gastrectomy are limited by the lack of trials directly comparing the two approaches.",
"      <br/>",
"      <br/>",
"      The choice of specific procedure (endoscopic mucosal resection or endoscopic submucosal dissection) will depend upon the size of the EGC, the depth of tumor invasion, and the preferences of the endoscopist performing the procedure. Gastrectomy with removal of perigastric lymph nodes is a reasonable alternative for patients who are willing to accept the increased morbidity associated with gastrectomy in order to have a more definitive procedure. (See",
"      <a class=\"local\" href=\"#H757935970\">",
"       'Endoscopic therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"       \"Overview of endoscopic resection of gastrointestinal tumors\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H757936019\">",
"       'Gastrectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H757935977\">",
"       'Standard and expanded criteria for endoscopic resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with EGC who have an incomplete endoscopic resection with positive vertical margins, piecemeal endoscopic resection, lymphovascular invasion, or submucosal involvement not meeting the expanded criteria for endoscopic resection, we recommend gastrectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with incomplete resections and only positive lateral margins may be considered for repeat endoscopic resection if there is no evidence of positive vertical margins, lymphovascular invasion, or submucosal involvement. (See",
"      <a class=\"local\" href=\"#H757935984\">",
"       'Endoscopic mucosal resection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H757936019\">",
"       'Gastrectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H757935977\">",
"       'Standard and expanded criteria for endoscopic resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also recommend gastrectomy for patients with EGC who do not meet standard or expanded criteria for endoscopic resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients who do not meet criteria for endoscopic resection are at increased risk for lymph node metastases, which are associated with tumor recurrence. Gastrectomy with removal of perigastric lymph nodes permits the evaluation and removal of involved lymph nodes. (See",
"      <a class=\"local\" href=\"#H757936019\">",
"       'Gastrectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H757935977\">",
"       'Standard and expanded criteria for endoscopic resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic gastrectomy is feasible and safe when conducted by surgeons experienced with the technique.&nbsp;Although this approach is clearly associated with a reduction in morbidity compared with open gastrectomy, additional data from high-quality comparative trials with long-term follow-up are needed before it can be confidently concluded that oncologic outcomes are comparable. (See",
"      <a class=\"local\" href=\"#H26621863\">",
"       'Laparoscopic gastrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      eradication therapy for patients with EGC (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment is important because",
"      <em>",
"       H. pylori",
"      </em>",
"      infection is associated with the development metachronous gastric cancer. In the event of negative biopsies for",
"      <em>",
"       H. pylori",
"      </em>",
"      , infection status should be determined with serology, as",
"      <em>",
"       H. pylori",
"      </em>",
"      organism loads may decrease with the onset of precancerous lesions and adenocarcinoma, thereby reducing biopsy sensitivity. (See",
"      <a class=\"local\" href=\"#H757936026\">",
"       'Anti-Helicobacter therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/1\">",
"      Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol 2006; 22:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/2\">",
"      Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005; 23:4490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/3\">",
"      Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/4\">",
"      Kang HJ, Kim DH, Jeon TY, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. Gastrointest Endosc 2010; 72:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/5\">",
"      Ahn JY, Jung HY, Choi KD, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011; 74:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/6\">",
"      Jee YS, Hwang SH, Rao J, et al. Safety of extended endoscopic mucosal resection and endoscopic submucosal dissection following the Japanese Gastric Cancer Association treatment guidelines. Br J Surg 2009; 96:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/7\">",
"      Lee JH, Choi MG, Min BH, et al. Predictive factors for lymph node metastasis in patients with poorly differentiated early gastric cancer. Br J Surg 2012; 99:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/8\">",
"      Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma: results of a retrospective analysis of 308 cases. Endoscopy 1994; 26:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/9\">",
"      Hiki Y, Shimao H, Mieno H, et al. Modified treatment of early gastric cancer: evaluation of endoscopic treatment of early gastric cancers with respect to treatment indication groups. World J Surg 1995; 19:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/10\">",
"      Uedo N, Iishi H, Tatsuta M, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006; 9:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/11\">",
"      Manner H, Rabenstein T, May A, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol 2009; 104:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/12\">",
"      Ahn JY, Jung HY, Choi JY, et al. Natural course of noncurative endoscopic resection of differentiated early gastric cancer. Endoscopy 2012; 44:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/13\">",
"      Yoon H, Kim SG, Choi J, et al. Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. Surg Endosc 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/14\">",
"      Nagano H, Ohyama S, Fukunaga T, et al. Indications for gastrectomy after incomplete EMR for early gastric cancer. Gastric Cancer 2005; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/15\">",
"      Horiki N, Omata F, Uemura M, et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period. Surg Endosc 2012; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/16\">",
"      Yamamoto H, Kita H. Endoscopic therapy of early gastric cancer. Best Pract Res Clin Gastroenterol 2005; 19:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/17\">",
"      Gotoda T. A large endoscopic resection by endoscopic submucosal dissection procedure for early gastric cancer. Clin Gastroenterol Hepatol 2005; 3:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/18\">",
"      Oka S, Tanaka S, Kaneko I, et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006; 64:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/19\">",
"      Ono H. Endoscopic submucosal dissection for early gastric cancer. Chin J Dig Dis 2005; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/20\">",
"      Takeuchi Y, Uedo N, Iishi H, et al. Endoscopic submucosal dissection with insulated-tip knife for large mucosal early gastric cancer: a feasibility study (with videos). Gastrointest Endosc 2007; 66:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/21\">",
"      Probst A, Pommer B, Golger D, et al. Endoscopic submucosal dissection in gastric neoplasia - experience from a European center. Endoscopy 2010; 42:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/22\">",
"      Cho KB, Jeon WJ, Kim JJ. Worldwide experiences of endoscopic submucosal dissection: not just Eastern acrobatics. World J Gastroenterol 2011; 17:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/23\">",
"      Nonaka S, Oda I, Nakaya T, et al. Clinical impact of a strategy involving endoscopic submucosal dissection for early gastric cancer: determining the optimal pathway. Gastric Cancer 2011; 14:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/24\">",
"      Endoscopy 2012; 10:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/25\">",
"      Oda I, Suzuki H, Nonaka S, Yoshinaga S. Complications of gastric endoscopic submucosal dissection. Dig Endosc 2013; 25 Suppl 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/26\">",
"      Jung H, Bae JM, Choi MG, et al. Surgical outcome after incomplete endoscopic submucosal dissection of gastric cancer. Br J Surg 2011; 98:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/27\">",
"      Abe N, Takeuchi H, Ohki A, et al. Long-term outcomes of combination of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer patients who have a potential risk of lymph node metastasis. Gastrointest Endosc 2011; 74:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/28\">",
"      Abe N, Mori T, Takeuchi H, et al. Laparoscopic lymph node dissection after endoscopic submucosal dissection: a novel and minimally invasive approach to treating early-stage gastric cancer. Am J Surg 2005; 190:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/29\">",
"      Choi KS, Jung HY, Choi KD, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011; 73:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/30\">",
"      Etoh T, Katai H, Fukagawa T, et al. Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointest Endosc 2005; 62:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/31\">",
"      Mimura S, Ito Y, Nagayo T, et al. Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer. Lasers Surg Med 1996; 19:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/32\">",
"      Nakamura H, Yanai H, Nishikawa J, et al. Experience with photodynamic therapy (endoscopic laser therapy) for the treatment of early gastric cancer. Hepatogastroenterology 2001; 48:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/33\">",
"      Ell C, Gossner L, May A, et al. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut 1998; 43:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/34\">",
"      Oguro Y. Laser endoscopic treatment for early gastric cancer. J Gastroenterol 1994; 29 Suppl 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/35\">",
"      Sibille A, Descamps C, Jonard P, et al. Endoscopic Nd:YAG treatment of superficial gastric carcinoma: experience in 18 Western inoperable patients. Gastrointest Endosc 1995; 42:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/36\">",
"      Yasuda K, Mizuma Y, Nakajima M, Kawai K. Endoscopic laser treatment for early gastric cancer. Endoscopy 1993; 25:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/37\">",
"      Kitamura T, Tanabe S, Koizumi W, et al. Argon plasma coagulation for early gastric cancer: technique and outcome. Gastrointest Endosc 2006; 63:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/38\">",
"      Tomita T, Arai E, Kohno T, et al. Outcomes of treatment of argon plasma coagulation therapy in elderly or high-risk patients with early gastric cancer: a comparison of outcomes among experienced and nonexperienced endoscopists. J Clin Gastroenterol 2011; 45:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/39\">",
"      Morita S, Katai H, Saka M, et al. Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Surg 2008; 95:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/40\">",
"      Mochiki E, Kamiyama Y, Aihara R, et al. Laparoscopic assisted distal gastrectomy for early gastric cancer: Five years' experience. Surgery 2005; 137:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/41\">",
"      Lee JH, Yom CK, Han HS. Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc 2009; 23:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/42\">",
"      Hiki N, Sano T, Fukunaga T, et al. Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg 2009; 209:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/43\">",
"      Katai H, Morita S, Saka M, et al. Long-term outcome after proximal gastrectomy with jejunal interposition for suspected early cancer in the upper third of the stomach. Br J Surg 2010; 97:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/44\">",
"      Ikeguchi M, Hatada T, Yamamoto M, et al. Evaluation of a pylorus-preserving gastrectomy for patients preoperatively diagnosed with early gastric cancer located in the middle third of the stomach. Surg Today 2010; 40:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/45\">",
"      Folli S, Dente M, Dell'Amore D, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg 1995; 82:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/46\">",
"      Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer 1993; 72:3174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/47\">",
"      Moreaux J, Bougaran J. Early gastric cancer. A 25-year surgical experience. Ann Surg 1993; 217:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/48\">",
"      Jentschura D, Heubner C, Manegold BC, et al. Surgery for early gastric cancer: a European one-center experience. World J Surg 1997; 21:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/49\">",
"      Hanazaki K, Wakabayashi M, Sodeyama H, et al. Surgical outcome in early gastric cancer with lymph node metastasis. Hepatogastroenterology 1997; 44:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/50\">",
"      Kitamura K, Yamaguchi T, Okamoto K, et al. Total gastrectomy for early gastric cancer. J Surg Oncol 1995; 60:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/51\">",
"      Kim JP, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol 1995; 2:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/52\">",
"      Shiozawa N, Kodama M, Chida T, et al. Recurrent death among early gastric cancer patients: 20-years' experience. Hepatogastroenterology 1994; 41:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/53\">",
"      Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005; 19:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/54\">",
"      Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008; 248:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/55\">",
"      Kitano S, Shiraishi N, Fujii K, et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002; 131:S306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/56\">",
"      Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010; 251:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/57\">",
"      Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 2005; 19:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/58\">",
"      Zeng YK, Yang ZL, Peng JS, et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 2012; 256:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/59\">",
"      Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/60\">",
"      Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/61\">",
"      Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/62\">",
"      Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/63\">",
"      Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012; 75:39.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (Accessed on September 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/65\">",
"      Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 2000; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/66\">",
"      Kohli Y, Kawai K, Fujita S. Analytical studies on growth of human gastric cancer. J Clin Gastroenterol 1981; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/67\">",
"      Maehara Y, Orita H, Okuyama T, et al. Predictors of lymph node metastasis in early gastric cancer. Br J Surg 1992; 79:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/68\">",
"      Everett SM, Axon AT. Early gastric cancer in Europe. Gut 1997; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/69\">",
"      Yasuda K, Shiraishi N, Suematsu T, et al. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer 1999; 85:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/70\">",
"      Okada K, Fujisaki J, Yoshida T, et al. Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. Endoscopy 2012; 44:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/71\">",
"      Youn HG, An JY, Choi MG, et al. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol 2010; 17:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/72\">",
"      Percivale P, Bertoglio S, Muggianu M, et al. Long-term postoperative results in 54 cases of early gastric cancer: the choice of surgical procedure. Eur J Surg Oncol 1989; 15:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/73\">",
"      Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997; 349:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/74\">",
"      Nakajima T, Oda I, Gotoda T, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/75\">",
"      Kim HH, Cho EJ, Noh E, et al. Missed synchronous gastric neoplasm with endoscopic submucosal dissection for gastric neoplasm: experience in our hospital. Dig Endosc 2013; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/76\">",
"      Seto Y, Nagawa H, Muto T. Impact of lymph node metastasis on survival with early gastric cancer. World J Surg 1997; 21:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/77\">",
"      Takeda J, Toyonaga A, Koufuji K, et al. Early gastric cancer in the remnant stomach. Hepatogastroenterology 1998; 45:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/78\">",
"      Kim JH, Kim HS, Seo WY, et al. External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer. Ann Oncol 2012; 23:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/79\">",
"      Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/80\">",
"      Ohashi S, Okamura S, Urano F, Maeda M. Clinicopathological variables associated with lymph node metastasis in submucosal invasive gastric cancer. Gastric Cancer 2007; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/81\">",
"      Tajima Y, Murakami M, Yamazaki K, et al. Risk factors for lymph node metastasis from gastric cancers with submucosal invasion. Ann Surg Oncol 2010; 17:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/82\">",
"      Roviello F, Rossi S, Marrelli D, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006; 94:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/83\">",
"      Kunisaki C, Akiyama H, Nomura M, et al. Significance of long-term follow-up of early gastric cancer. Ann Surg Oncol 2006; 13:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/84\">",
"      Torii A, Sakai M, Inoue K, et al. A clinicopathological analysis of early gastric cancer: retrospective study with special reference to lymph node metastasis. Cancer Detect Prev 1994; 18:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/85\">",
"      Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/87\">",
"      Mitsuhashi T, Lauwers GY, Ban S, et al. Post-gastric endoscopic mucosal resection surveillance biopsies: evaluation of mucosal changes and recognition of potential mimics of residual adenocarcinoma. Am J Surg Pathol 2006; 30:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/46/4842/abstract/88\">",
"      Kato M, Nishida T, Yamamoto K, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16858 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4842=[""].join("\n");
var outline_f4_46_4842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H757938171\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H762443442\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757935963\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757935970\">",
"      Endoscopic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H757935977\">",
"      - Standard and expanded criteria for endoscopic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H757935984\">",
"      - Endoscopic mucosal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H153456916\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H757935991\">",
"      Management of incomplete resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H757935998\">",
"      - Endoscopic submucosal dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H757936005\">",
"      - Endoscopic resection versus gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H757936012\">",
"      - Other endoscopic modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936019\">",
"      Gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26621863\">",
"      - Laparoscopic gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936026\">",
"      Anti-Helicobacter therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936033\">",
"      Adjuvant therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757936040\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936047\">",
"      Prognosis without treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936054\">",
"      Prognosis following treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757936061\">",
"      Prognosis with lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757936068\">",
"      POST-TREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757938171\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/16858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/53/37726\" title=\"figure 1\">",
"      Early gastric cancer survival nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13195\" title=\"table 1\">",
"      Paris classification system of superficial lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/35/19003\" title=\"table 2\">",
"      JSGE classification of endoluminal cancers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19333?source=related_link\">",
"      Local palliation for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/28/32195?source=related_link\">",
"      Patient information: Stomach cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_46_4843="C-S rate by Bishop score no PG";
var content_f4_46_4843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cesarean delivery rate (percent) for failed induction by Bishop score and parity, circa 1985 (prior to availability of prostaglandins)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bishop score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nullipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multipara",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-3",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-10",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Arulkumaran, S, Gibb, DM, TambyRaja, RL, et al. Aust N Z J Obstet Gynaecol 1985; 25:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4843=[""].join("\n");
var outline_f4_46_4843=null;
var title_f4_46_4844="RTOG LENT criteria";
var content_f4_46_4844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiation therapy oncology group (RTOG) criteria for long-term normal tissue toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frequent loose bowel movements without associated rectal irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Proctitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rectal irritation or urgency, and the presence of mucous or",
"blood in the stool, with or without frequent or sometimes loose bowel",
"movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irritative bladder symptoms such as frequent dysuria; hematuria may or may not be a part of the clinical picture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minor symptoms requiring no treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Symptoms that respond to simple outpatient management, and do not affect lifestyle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distressing",
"symptoms affecting lifestyle; may necessitate hospital admission or",
"minor surgical intervention (eg, urethral dilation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major surgical intervention or long stay in the hospital necessary (eg, laparotomy, colostomy, or cystectomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatal complications",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rubin P. Int J Radiat Oncol Biol Phys 1995; 31:1035.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4844=[""].join("\n");
var outline_f4_46_4844=null;
var title_f4_46_4845="DRI selected nutrients children";
var content_f4_46_4845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated energy requirements (low activity) and recommended dietary allowance (RDA) of selected nutrients for infants, children, and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Energy",
"        <br/>",
"        (kcal/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"        <br/>",
"        (g/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total",
"        <br/>",
"        (fat g/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iron",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcium",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Zinc",
"        <br/>",
"        (mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        1-3 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        850-1300",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        750-1250",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        4-8 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        1400-1700",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        1300-1600",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        9-13 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        1800-2300",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        1700-2000",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        14-18 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        2500-2800",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        25-35",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        The Dietary Reference Intakes, National Academy of Sciences, Washington, DC, 2002.",
"       </li>",
"       <li>",
"        National Academies Press. Dietary Reference Intakes for Calcium and Vitamin D (2010). Available at",
"        <a href=\"file://books.nap.edu/openbook.php?record_id=13050&amp;page=291\" target=\"_blank\">",
"         file://books.nap.edu/openbook.php?record_id=13050&amp;page=291",
"        </a>",
"        . Accessed on December 13, 2010.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4845=[""].join("\n");
var outline_f4_46_4845=null;
var title_f4_46_4846="Switching between different methods of contraception";
var content_f4_46_4846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Switching between different methods of contraception",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pill",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patch",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Progestin shot",
"        <br/>",
"        (\"Depo\")",
"       </td>",
"       <td class=\"subtitle1\">",
"        Progestin implant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hormone IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Copper IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pill",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         No gap:",
"        </strong>",
"        take 1st pill of new pack the day after taking any pill in old pack",
"       </td>",
"       <td>",
"        Start patch",
"        <strong>",
"         1 day before",
"        </strong>",
"        stopping pill",
"       </td>",
"       <td>",
"        <strong>",
"         No gap:",
"        </strong>",
"        insert ring the day after taking any pill in pack",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping pill",
"       </td>",
"       <td>",
"        Insert implant",
"        <strong>",
"         4 days before",
"        </strong>",
"        stopping pill",
"       </td>",
"       <td>",
"        Insert hormone IUD",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping pill",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         up to 5 days after",
"        </strong>",
"        stopping pill",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Patch",
"        </strong>",
"       </td>",
"       <td>",
"        Start pill",
"        <strong>",
"         1 day before",
"        </strong>",
"        stopping patch",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <strong>",
"         No gap:",
"        </strong>",
"        insert ring and remove patch on the same day",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping patch",
"       </td>",
"       <td>",
"        Insert implant",
"        <strong>",
"         4 days before",
"        </strong>",
"        stopping patch",
"       </td>",
"       <td>",
"        Insert hormone IUD",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping patch",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         up to 5 days after",
"        </strong>",
"        stopping patch",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Ring",
"        </strong>",
"       </td>",
"       <td>",
"        Start pill",
"        <strong>",
"         1 day before",
"        </strong>",
"        stopping ring",
"       </td>",
"       <td>",
"        Start patch",
"        <strong>",
"         2 days before",
"        </strong>",
"        stopping ring",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping ring",
"       </td>",
"       <td>",
"        Insert implant",
"        <strong>",
"         4 days before",
"        </strong>",
"        stopping ring",
"       </td>",
"       <td>",
"        Insert hormone IUD",
"        <strong>",
"         7 days before",
"        </strong>",
"        stopping ring",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         up to 5 days after",
"        </strong>",
"        stopping ring",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Progestin shot",
"         <br/>",
"         (\"Depo\")",
"        </strong>",
"       </td>",
"       <td>",
"        Can take 1st pill",
"        <strong>",
"         up to 15 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"       <td>",
"        Can start patch",
"        <strong>",
"         up to 15 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"       <td>",
"        Can insert ring",
"        <strong>",
"         up to 15 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Can insert implant",
"        <strong>",
"         up to 15 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"       <td>",
"        Can insert hormone IUD",
"        <strong>",
"         up to 15 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         up to 16 weeks after",
"        </strong>",
"        the last shot",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Progestin implant",
"        </strong>",
"       </td>",
"       <td>",
"        Start pill",
"        <strong>",
"         7 days before",
"        </strong>",
"        implant is removed",
"       </td>",
"       <td>",
"        Start patch",
"        <strong>",
"         7 days before",
"        </strong>",
"        implant is removed",
"       </td>",
"       <td>",
"        Start ring",
"        <strong>",
"         7 days before",
"        </strong>",
"        implant is removed",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        implant is removed",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Insert hormone IUD",
"        <strong>",
"         7 days before",
"        </strong>",
"        implant is removed",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         up to 5 days after",
"        </strong>",
"        implant is removed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Hormone IUD",
"        </strong>",
"       </td>",
"       <td>",
"        Start pill",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Start patch",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Start ring",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Insert implant",
"        <strong>",
"         4 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Can insert copper IUD",
"        <strong>",
"         right after",
"        </strong>",
"        hormone IUD is removed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Copper IUD",
"        </strong>",
"       </td>",
"       <td>",
"        Start pill",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Start patch",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Start ring",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        First shot",
"        <strong>",
"         7 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Insert implant",
"        <strong>",
"         4 days before",
"        </strong>",
"        IUD is removed",
"       </td>",
"       <td>",
"        Insert hormone IUD",
"        <strong>",
"         right after",
"        </strong>",
"        copper IUD is removed and use back-up method for",
"        <strong>",
"         7 days",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the Reproductive Health Access Project (",
"     <a href=\"file://www.reproductiveaccess.org\" target=\"_blank\">",
"      file://www.reproductiveaccess.org",
"     </a>",
"     ). Available at:",
"     <a href=\"file://www.reproductiveaccess.org/contraception/downloads/switching_bc.pdf\" target=\"_blank\">",
"      file://www.reproductiveaccess.org/contraception/downloads/switching_bc.pdf",
"     </a>",
"     . Accessed March 29th, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4846=[""].join("\n");
var outline_f4_46_4846=null;
var title_f4_46_4847="Barretts pre PDT";
var content_f4_46_4847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of Barrett's esophagus prior to treatment. The salmon-colored tongues of Barrett's mucosa are visible in the background of the the pale, pink squamous mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marta Davila, MD and Jacques Van Dam, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_46_4847=[""].join("\n");
var outline_f4_46_4847=null;
        